The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Engineering of anti-platelet antibodies for the diagnosis and therapy of infants with bleeding disorders. Foeto-maternal alloimmune thrombocytopenia (FMAIT) is a serious clinical condition where infants suffer potentially fatal bleeding disorders from 14 weeks gestation to 1-2 weeks post delivery. The cause of the disease is through maternal antibodies destroying foetal platelets. Our aim is to produce human antibodies, which will be used as diagnostic agents to screen for the condition in preg ....Engineering of anti-platelet antibodies for the diagnosis and therapy of infants with bleeding disorders. Foeto-maternal alloimmune thrombocytopenia (FMAIT) is a serious clinical condition where infants suffer potentially fatal bleeding disorders from 14 weeks gestation to 1-2 weeks post delivery. The cause of the disease is through maternal antibodies destroying foetal platelets. Our aim is to produce human antibodies, which will be used as diagnostic agents to screen for the condition in pregnant women, and to further develop such antibodies for therapy. Identification of mothers at risk of FMAIT and the development of a specific therapy are vital to the management and prevention of this serious condition.Read moreRead less
Dissecting the Indigo Pathway in Natural Indigo Producing Plants: Intricate Pathway Engineering for the Generation of Blue-Fibre Cotton. Australian cotton growers must maintain a sustained competitive advantage in the future to compete within the global cotton market by commanding higher margins for specialty cotton lint over and above current revenues. Development, via biotechnology, of naturally-colored, 'blue' lint cottons is the technical goal, where novel environmentally-benign textile prod ....Dissecting the Indigo Pathway in Natural Indigo Producing Plants: Intricate Pathway Engineering for the Generation of Blue-Fibre Cotton. Australian cotton growers must maintain a sustained competitive advantage in the future to compete within the global cotton market by commanding higher margins for specialty cotton lint over and above current revenues. Development, via biotechnology, of naturally-colored, 'blue' lint cottons is the technical goal, where novel environmentally-benign textile products could be produced without the use of toxic synthetic dyes or caustic dyeing processes. Success will provide a unique opportunity to re-establish an Australian cotton/textile industry by allowing direct participation in the development, branding and marketing of novel Australian textile products, generating potential revenue upwards of $10B/year. Read moreRead less